PMID- 35911710
OWN - NLM
STAT- MEDLINE
DCOM- 20220802
LR  - 20220811
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Susceptibility and Severity of COVID-19 Are Both Associated With Lower Overall 
      Viral-Peptide Binding Repertoire of HLA Class I Molecules, Especially in Younger 
      People.
PG  - 891816
LID - 10.3389/fimmu.2022.891816 [doi]
LID - 891816
AB  - An important number of studies have been conducted on the potential association 
      between human leukocyte antigen (HLA) genes and COVID-19 susceptibility and 
      severity since the beginning of the pandemic. However, case-control and 
      peptide-binding prediction methods tended to provide inconsistent conclusions on 
      risk and protective HLA alleles, whereas some researchers suggested the 
      importance of considering the overall capacity of an individual's HLA Class I 
      molecules to present SARS-CoV-2-derived peptides. To close the gap between these 
      approaches, we explored the distributions of HLA-A, -B, -C, and -DRB1 1st-field 
      alleles in 142 Iranian patients with COVID-19 and 143 ethnically matched healthy 
      controls, and applied in silico predictions of bound viral peptides for each 
      individual's HLA molecules. Frequency comparison revealed the possible 
      predisposing roles of HLA-A*03, B*35, and DRB1*16 alleles and the protective 
      effect of HLA-A*32, B*58, B*55, and DRB1*14 alleles in the viral infection. None 
      of these results remained significant after multiple testing corrections, except 
      HLA-A*03, and no allele was associated with severity, either. Compared to peptide 
      repertoires of individual HLA molecules that are more likely population-specific, 
      the overall coverage of virus-derived peptides by one's HLA Class I molecules 
      seemed to be a more prominent factor associated with both COVID-19 susceptibility 
      and severity, which was independent of affinity index and threshold chosen, 
      especially for people under 60 years old. Our results highlight the effect of the 
      binding capacity of different HLA Class I molecules as a whole, and the more 
      essential role of HLA-A compared to HLA-B and -C genes in immune responses 
      against SARS-CoV-2 infection.
CI  - Copyright (c) 2022 Basir, Majzoobi, Ebrahimi, Noroozbeygi, Hashemi, Keramat, 
      Mamani, Eini, Alizadeh, Solgi and Di.
FAU - Basir, Hamid Reza Ghasemi
AU  - Basir HRG
AD  - Department of Pathology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Majzoobi, Mohammad Mahdi
AU  - Majzoobi MM
AD  - Brucellosis Research Centre, Hamadan University of Medical Sciences, Hamadan, 
      Iran.
FAU - Ebrahimi, Samaneh
AU  - Ebrahimi S
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Noroozbeygi, Mina
AU  - Noroozbeygi M
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Hashemi, Seyed Hamid
AU  - Hashemi SH
AD  - Brucellosis Research Centre, Hamadan University of Medical Sciences, Hamadan, 
      Iran.
FAU - Keramat, Fariba
AU  - Keramat F
AD  - Brucellosis Research Centre, Hamadan University of Medical Sciences, Hamadan, 
      Iran.
FAU - Mamani, Mojgan
AU  - Mamani M
AD  - Brucellosis Research Centre, Hamadan University of Medical Sciences, Hamadan, 
      Iran.
FAU - Eini, Peyman
AU  - Eini P
AD  - Brucellosis Research Centre, Hamadan University of Medical Sciences, Hamadan, 
      Iran.
FAU - Alizadeh, Saeed
AU  - Alizadeh S
AD  - Department of Radiology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Solgi, Ghasem
AU  - Solgi G
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Di, Da
AU  - Di D
AD  - Anthropology Unit, Department of Genetics and Evolution, University of Geneva, 
      Geneva, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20220707
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (HLA-A Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Viral Proteins)
SB  - IM
MH  - *COVID-19/genetics
MH  - HLA-A Antigens/genetics/metabolism
MH  - *Histocompatibility Antigens Class I/genetics/metabolism
MH  - Humans
MH  - Iran
MH  - Middle Aged
MH  - Protein Binding
MH  - SARS-CoV-2
MH  - *Viral Proteins/metabolism
PMC - PMC9331187
OTO - NOTNLM
OT  - COVID-19
OT  - HLA
OT  - HLA binding prediction
OT  - SARS-CoV-2-derived peptides
OT  - overall binding repertoire
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/02 06:00
MHDA- 2022/08/03 06:00
PMCR- 2022/07/07
CRDT- 2022/08/01 03:50
PHST- 2022/03/08 00:00 [received]
PHST- 2022/06/10 00:00 [accepted]
PHST- 2022/08/01 03:50 [entrez]
PHST- 2022/08/02 06:00 [pubmed]
PHST- 2022/08/03 06:00 [medline]
PHST- 2022/07/07 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.891816 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jul 7;13:891816. doi: 10.3389/fimmu.2022.891816. eCollection 
      2022.